Fig. 3.

Predicted improvements in HbA1c. Prediction of HbA1c reduction and achievement of different glycemic targets were calculated among 1869 patients using oral semaglutide only as add-on therapy. A Estimates done using data from RCTs (PIONEER 2,3,7). B Estimates done using data from the IGNITE real-world evidence (RWE) study. C Comparison of expected benefit (proportion of subjects achieving HbA1c < 7%) from the addition of oral semaglutide versus empagliflozin or sitagliptin, among n = 1259 subjects without SGLT-2 or DPP-4 inhibitors as background regimen